Utilizing microRNA in cerebrospinal fluid to evaluate the effects of tyrosine kinase inhibition via Nilotinib on gene regulation in individuals with Parkinson's disease or Alzheimer's disease
Utilizing microRNA in cerebrospinal fluid to evaluate the effects of tyrosine kinase inhibition via Nilotinib on gene regulation in individuals with Parkinson's disease or Alzheimer's disease